Health

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

EPALINGES, Switzerland, Oct. 28, 2025 /PRNewswire/ -- Onward Therapeutics SA, a clinical stage oncology company, today announced that its French subsidiary, Onward Therapeutics France, has exercised its exclusive option and entered into a worldwide license agreement with Institut du Cancer de Mon...

2025-10-28 08:00 803

Nippon Shinyaku Selects LifeSphere® Safety

Japan-based Nippon Shinyaku has chosen LifeSphere MultiVigilance as new case processing database TOKYO, Oct. 28, 2025 /PRNewswire/ -- ArisGlobal , an AI-first technology comp...

2025-10-28 07:00 1078

Vietnam Healthcare Summit 2025: Powering Transformation of Vietnam's Healthcare Landscape Through Innovation and Investment

HO CHI MINH CITY, Vietnam, Oct. 28, 2025 /PRNewswire/ -- Vietnam Innovators Digest successfully hosted the Vietnam Healthcare Summit 2025 under the theme  "Making Vietnam an Innovation Hub Through Healthcare", held at JW Marriott Hotel & Suites Saigon. The event gathered over200 healthcare leaders...

2025-10-28 01:31 1340

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion o...

2025-10-27 22:46 970

The WEMP Foundation and Rafa Nadal Foundation are joining together to Support Total Wellbeing of Children and Youth through Play

HONG KONG, Oct. 27, 2025 /PRNewswire/ -- The WEMP Foundation (WEMP, which stands for "Wellbeing", "EQ", "Mental Health", and "Parenting") and theRafal Nadal Foundation (RNF) are delighted to announce their alliance for supporting total wellbeingof children and youth around the world through Play....

2025-10-27 22:13 1163

Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion o...

2025-10-27 21:00 828

Kolmar Korea Selected for Government-Led 'AI Factory' Initiative -- Driving Innovation in K-Beauty Manufacturing

* The only cosmetics company chosen by the Ministry of Trade, Industry and Resources for the "AI Factory" project * Enables agile, small-batch, multi-product production to meet diverse client needs in real time SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Kolmar Korea

2025-10-27 20:30 4016

BioDlink Completes First International Shipment of Bevacizumab to Colombia

* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...

2025-10-27 20:30 934

National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability

SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ -- The highly anticipated 2025 IDF World Dairy Summit took place fromOctober 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the dairy industry. Liu Chunxi, Chairman of the National Ce...

2025-10-27 19:23 1038

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) p...

2025-10-27 19:15 1726

China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)

Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype of lung cancer Breakthrough Therapy designation will allow for an expedited development and regulatory review of gotistobart inChina Globa...

2025-10-27 19:00 940

Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial

* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study * 94 patients enrolled out of 102 planned across Korea and the U.S.  * Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct...

2025-10-27 19:00 998

Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025

-Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenan...

2025-10-27 18:00 1160

MINISH Technology Has Successfully Concluded Its First U.S. MINISH Veneers Course, Certifying 22 Dentists

SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Health-tech company MINISH Technology Inc. announced on the 27th that 22 dentists completed its 15th MINISH Course, the first session held for local practitioners inthe United States.

2025-10-27 14:58 955

Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials

SINGAPORE, Oct. 27, 2025 /PRNewswire/ -- Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, mar...

2025-10-27 13:22 1076

KLN Named Exclusive Distributor for Siemens Healthineers

Point-of-Care Testing Solutions in Hong Kong HONG KONG, Oct. 27, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announces a strategic partnership between its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), and global medical technology leader Siemens Hea...

2025-10-27 12:00 1002

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL

2025-10-27 11:23 1799

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer

SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...

2025-10-27 09:51 925

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...

2025-10-27 09:00 880

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...

2025-10-27 08:00 1097
1 ... 24252627282930 ... 874

Week's Top Stories